Full Text View
Tabular View
No Study Results Posted
Related Studies
Lactulose Supplementation in Premature Infants
This study has been completed.
Study NCT00616876   Information provided by Bnai Zion Medical Center
First Received: February 5, 2008   Last Updated: February 14, 2008   History of Changes

February 5, 2008
February 14, 2008
February 2005
August 2006   (final data collection date for primary outcome measure)
lactulose would support the early growth of Lactobacilli in the stools of premature infants [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00616876 on ClinicalTrials.gov Archive Site
lactulose would also improve nutritional status and decrease NEC and late-onset sepsis in preterm infants [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Same as current
 
Lactulose Supplementation in Premature Infants
The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study

A pilot study to test the safety of use of lactulose in preterm infants and to preliminary assess the hypothesis that lactulose would support the early growth of Lactobacilli in the stools of premature infants and possibly would also improve nutritional status and decrease NEC and late-onset sepsis.

Prospective, double-blind, placebo-controlled single center pilot study in 23-34 weeks gestation premature infants. Study group will receive 1% lactulose, while control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula). Clinical parameters will be followed. Stool samples will be sent for culture.

Phase II
Interventional
Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study
  • Necrotizing Enterocolitis
  • Sepsis
  • Drug: Lactulose
  • Dietary Supplement: Dextrose
  • Experimental: Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
  • Placebo Comparator: Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
28
January 2007
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

Premature infants were recruited based on the following criteria:

  • 23-34 weeks' gestation (as determined by a combination of maternal dates, early prenatal ultrasonography and postnatal gestational age estimation based on physical and neuromuscular signs (New Ballard Score), as long as there will be gestational age agreement between the 3 methods < 2 weeks);
  • Absence of major congenital malformations; and
  • Informed consent obtained from parents.

Exclusion Criteria:

  • Major congenital malformations and parental refusal.
Both
23 Weeks to 34 Weeks
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00616876
Arieh Riskin MD, Bnai Zion Medical Center
BZ-23/04, LacPre18
Bnai Zion Medical Center
 
Principal Investigator: Arieh Riskin, MD Department of Neonatology, Bnai Zion Medical Center
Principal Investigator: Ron Shaoul, MD Department of Pediatrics, Pediatric Gastroenterology, Bnai Zion Medical Center
Bnai Zion Medical Center
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP